{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:16:01Z","timestamp":1778260561793,"version":"3.51.4"},"reference-count":15,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>SMARCA4-deficient undifferentiated cervical carcinoma is an extremely rare and aggressive malignancy, and effective treatment options are lacking. We experienced a rare case involving a patient with SMARCA4-deficient undifferentiated cervical carcinoma who was successfully managed in the long term. A woman in her 40s presented with a chief complaint of abnormal vaginal bleeding. A cervical biopsy revealed adenocarcinoma; thus, radical hysterectomy was performed with R0 tumour resection. Histopathological examination of the resected tumour showed rhabdoid features under (H&amp;E) staining and negativity for SMARCA4 under immunohistochemical staining. Given the poor prognosis associated with SMARCA4-deficient carcinoma, adjuvant radiotherapy was added. Follow-up for more than a year revealed no evidence of recurrence. For undifferentiated cervical carcinoma with rhabdoid features on H&amp;E staining, SMARCA4 immunostaining may be considered for risk classification and recurrence prevention. R0 resection and postoperative adjuvant radiotherapy may contribute to a good prognosis for patients with SMARCA4-deficient carcinoma.<\/jats:p>","DOI":"10.1136\/bcr-2023-258711","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:50:13Z","timestamp":1736031013000},"page":"e258711","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment for SMARCA4-deficient carcinoma of uterine cervix"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-0464","authenticated-orcid":false,"given":"Takuya","family":"Yokoe","sequence":"first","affiliation":[{"name":"Kansai Medical University, Hirakata Hospital, Hirakata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaede","family":"Oku","sequence":"additional","affiliation":[{"name":"Kansai Medical University, Hirakata Hospital, Hirakata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Noda","sequence":"additional","affiliation":[{"name":"Kansai Medical University, Hirakata Hospital, Hirakata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kita","sequence":"additional","affiliation":[{"name":"Kansai Medical University, Hirakata Hospital, Hirakata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"2025082801152458000_18.1.e258711.1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.semdp.2020.08.003","article-title":"SWI\/SNF-deficient malignancies of the female genital tract","volume":"38","author":"McCluggage","year":"2021","journal-title":"Semin Diagn Pathol"},{"key":"2025082801152458000_18.1.e258711.2","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.1610003","article-title":"SMARCA4-Deficient Carcinoma of Uterine Cervix Resembling SCCOHT-Case Report","volume":"27","author":"Sir\u00e1k","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"2025082801152458000_18.1.e258711.3","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1995.1203"},{"key":"2025082801152458000_18.1.e258711.4","first-page":"120","article-title":"Malignant rhabdoid tumour of the uterine cervix","volume":"108","author":"Tsuda","year":"2001","journal-title":"BJOG"},{"key":"2025082801152458000_18.1.e258711.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2015.06.001"},{"key":"2025082801152458000_18.1.e258711.6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1066896919865944","article-title":"SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Review of Literature","volume":"28","author":"Stewart","year":"2020","journal-title":"Int J Surg Pathol"},{"key":"2025082801152458000_18.1.e258711.7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13023-014-0126-4","article-title":"In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model","volume":"9","author":"Otte","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"2025082801152458000_18.1.e258711.8","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2931"},{"key":"2025082801152458000_18.1.e258711.9","doi-asserted-by":"publisher","DOI":"10.1177\/1066896920959453"},{"key":"2025082801152458000_18.1.e258711.10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/10668969221095266","article-title":"SMARCA4-deficient Undifferentiated Uterine Sarcoma: Clinicopathological Features of an Emerging Entity","volume":"31","author":"Nakra","year":"2023","journal-title":"Int J Surg Pathol"},{"key":"2025082801152458000_18.1.e258711.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.crwh.2020.e00231","article-title":"SMARCA4-deficient uterine sarcoma: A case report and a concise review","volume":"27","author":"Kord","year":"2020","journal-title":"Case Rep Womens Health"},{"key":"2025082801152458000_18.1.e258711.12","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2018.832","article-title":"Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach","volume":"12","author":"Qin","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"2025082801152458000_18.1.e258711.13","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206451"},{"key":"2025082801152458000_18.1.e258711.14","unstructured":"US National Library of Medicine . A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed\/refractory synovial sarcoma. n.d. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02601950"},{"key":"2025082801152458000_18.1.e258711.15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41467-018-06958-9","article-title":"CDK4\/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary","volume":"10","author":"Xue","year":"2019","journal-title":"Nat Commun"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-258711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:15:35Z","timestamp":1756368935000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-258711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,4]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bcr-2023-258711"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-258711","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}